Identification of a Potential Molecular Diagnostic Biomarker in Keloid Disease: Syndecan-1 (CD138) Is Overexpressed in Keloid Scar Tissue

Bagabir, Rania A; Syed, Farhatullah; Shenjere, Patrick; Paus, Ralf

doi:10.1016/j.jid.2016.06.623

Cited by 14 publications

(11 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…By contrast, lesions with JSS 2015 scores of 16 points or more have strong keloid properties and tend to resist treatment. Thus, the JSS 2015 classification appears to reflect clinical reality.Biomarkers that can clearly distinguish keloids from hypertrophic scars have not yet been found, despite the many studies that have searched for them [6]. Systemic factors can influence keloid and hypertrophic scar progression: both lesion forms are known to worsen in pregnant women [7, 8] and in patients with hypertension [9].…”

Section: Main Contextmentioning

confidence: 99%

Diagnosis and Treatment of Keloids and Hypertrophic Scars—Japan Scar Workshop Consensus Document 2018

et al. 2019

View full text Add to dashboard Cite

There has been a long-standing need for guidelines on the diagnosis and treatment of keloids and hypertrophic scars that are based on an understanding of the pathomechanisms that underlie these skin fibrotic diseases. This is particularly true for clinicians who deal with Asian and African patients because these ethnicities are highly prone to these diseases. By contrast, Caucasians are less likely to develop keloids and hypertrophic scars, and if they do, the scars tend not to be severe. This ethnic disparity also means that countries vary in terms of their differential diagnostic algorithms. The lack of clear treatment guidelines also means that primary care physicians are currently applying a hotchpotch of treatments, with uneven outcomes. To overcome these issues, the Japan Scar Workshop (JSW) has created a tool that allows clinicians to objectively diagnose and distinguish between keloids, hypertrophic scars, and mature scars. This tool is called the JSW Scar Scale (JSS) and it involves scoring the risk factors of the individual patients and the affected areas. The tool is simple and easy to use. As a result, even physicians who are not accustomed to keloids and hypertrophic scars can easily diagnose them and judge their severity. The JSW has also established a committee that, in cooperation with outside experts in various fields, has prepared a Consensus Document on keloid and hypertrophic scar treatment guidelines. These guidelines are simple and will allow even inexperienced clinicians to choose the most appropriate treatment strategy. The Consensus Document is provided in this article. It describes (1) the diagnostic algorithm for pathological scars and how to differentiate them from clinically similar benign and malignant tumors, (2) the general treatment algorithms for keloids and hypertrophic scars at different medical facilities, (3) the rationale behind each treatment for keloids and hypertrophic scars, and (4) the body site-specific treatment protocols for these scars. We believe that this Consensus Document will be helpful for physicians from all over the world who treat keloids and hypertrophic scars.

show abstract

Section: Main Contextmentioning

confidence: 99%

Diagnosis and Treatment of Keloids and Hypertrophic Scars—Japan Scar Workshop Consensus Document 2018

et al. 2019

View full text Add to dashboard Cite

show abstract

“…37 One other overexpressed immune molecule in keloid scar tissue is syndecan-1 (CD138), identified as one of the potential biomarkers for keloid disease diagnosis. 38 Several in vitro studies have explored the stimulation of certain cytokines on KFs in monolayer cultures. 39,40 For instance, connective tissue growth factor (CTGF), was demonstrated to be involved in intracellular signaling pathways in KFs.…”

Section: Two-dimensional Monolayer Culture Modelsmentioning

confidence: 99%

In VitroandEx VivoModels for Functional Testing of Therapeutic Anti-scarring Drug Targets in Keloids

Sharma

Lebeko

Kidzeru

et al. 2019

Advances in Wound Care

Self Cite

View full text Add to dashboard Cite

Keloids are benign fibro-proliferative raised dermal lesions that spread beyond the original borders of the wound, continue to grow, rarely regress, and are the most common in pigmented individuals after an abnormal wound healing response. The current treatment failure and respective challenges involved highlighting the underlying issue that the etiopathogenesis of keloids is still not well understood. Disease models are required to better understand the disease pathogenesis. It is not possible to establish keloids in animals because of the uniqueness of this disease to human skin. To address this challenge, along these lines, non-animal reproducible models are vital in investigating molecular mechanisms of keloid pathogenesis and therapeutics development. Recent Advances: Various non-animal models have been developed to better understand the molecular mechanisms involved in keloid scarring and aid in identifying and evaluating the therapeutic potential of novel drug candidates. In this scenario, the current review aims at describing in vitro monocultures, co-cultures, organotypic cultures, and ex vivo whole skin keloid tissue organ culture models. Critical Issues and Future Directions: Current treatment options for keloids are far from securing a cure or preventing disease recurrence. Identifying universally accepted effective therapy for keloids has been hampered by the absence of appropriate disease model systems. Animal models do not accurately mimic the disease, thus non-animal model systems are pivotal in keloid research. The use of these models is essential not only for a better understanding of disease biology but also for identifying and evaluating novel drug targets.

show abstract

“…Its levels are raised in fibrotic dermis, due to the induction of TGFβ and the insulin-like growth factor binding protein-3 (IGFBP-3) [195]. Syndecan-1 is also overexpressed in keloid scars compared to normal or hypertrophic scars [196].…”

Section: Syndecansmentioning

confidence: 99%

Interplay between Cell-Surface Receptors and Extracellular Matrix in Skin

Kleiser

Nyström

2020

Biomolecules

View full text Add to dashboard Cite

Skin consists of the epidermis and dermis, which are connected by a specialized basement membrane—the epidermal basement membrane. Both the epidermal basement membrane and the underlying interstitial extracellular matrix (ECM) created by dermal fibroblasts contain distinct network-forming macromolecules. These matrices play various roles in order to maintain skin homeostasis and integrity. Within this complex interplay of cells and matrices, cell surface receptors play essential roles not only for inside-out and outside-in signaling, but also for establishing mechanical and biochemical properties of skin. Already minor modulations of this multifactorial cross-talk can lead to severe and systemic diseases. In this review, major epidermal and dermal cell surface receptors will be addressed with respect to their interactions with matrix components as well as their roles in fibrotic, inflammatory or tumorigenic skin diseases.

show abstract

Identification of a Potential Molecular Diagnostic Biomarker in Keloid Disease: Syndecan-1 (CD138) Is Overexpressed in Keloid Scar Tissue

Cited by 14 publications

References 18 publications

Diagnosis and Treatment of Keloids and Hypertrophic Scars—Japan Scar Workshop Consensus Document 2018

Diagnosis and Treatment of Keloids and Hypertrophic Scars—Japan Scar Workshop Consensus Document 2018

In VitroandEx VivoModels for Functional Testing of Therapeutic Anti-scarring Drug Targets in Keloids

Interplay between Cell-Surface Receptors and Extracellular Matrix in Skin

Contact Info

Product

Resources

About